CoRegen
CoRegen, Inc. (CoRegen Science) is a clinical-stage biopharmaceutical company in Houston, Texas developing adoptive cell therapies for aggressive solid tumors. Its platform, licensed exclusively from the O'Malley Lab at Baylor College of Medicine, uses CRISPR gene editing to knock out the SRC-3 steroid receptor coactivator gene in regulatory T (Treg) cells, reprogramming them from immunosuppressors into tumor-killing effectors. The lead program, CRG-150, received FDA IND clearance for a first-in-human Phase 1/2a trial in advanced solid tumors, and the underlying science won the 2023 Cozzarelli Prize. CoRegen is a therapeutics organization, not a software company: it publishes a nine-page marketing and science site (about, the science, preclinical studies, pipeline, publications, leadership, news, careers, contact) and no developer program, API, SDK, or machine-readable specification of any kind.
CoRegen is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Oncology, and Cell Therapy.
Kin Score
Standards implemented 1
Standards this provider implements or carries. De facto ones are profiled and measured by the API Commons; formal ones come from the standards directory and are linked by the provider's own tags. The evidence column says how each claim was established — not that it was made.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Other 6
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.